Company intelligence / Profile preview
Ambulero
Miami, Florida, United Statesambulero.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
AMB-301 (AAV gene therapy) received US FDA Orphan Drug designation for Buerger’s Disease with >10 years basic research and promising animal data. IND-enabling studies are underway; clinical trials planned. Preclinical results show therapeutic angiogenesis, muscle regeneration, and improved blood flow in animal models.
- Therapeutic areas
- CardiovascularDermatology
- Modalities
- Cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Orphinic ScientificUniversity of Miami
Beyond the preview
Go deeper on Ambulero.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ambulero.